More than just a “cosmetic issue,” breast asymmetry can have negative psychological and emotional effects, according to the study by ASPS Member Surgeon Dr. Brian I. Labow and colleagues of Boston Children’s Hospital…
Glenn E. Palomaki, PhD, associate director of the Division of Medical Screening and Special Testing in the Department of Pathology and Laboratory Medicine at Women & Infants Hospital of Rhode Island has recently published an invited commentary in the November issue of Genetics in Medicine…
Researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J…
What are exosomes? Exosomes are small vesicles which are secreted by all cells and contain proteins and messenger RNAs and microRNAs…
A novel medical-imaging technology, TexRAD, which analyses the texture of tumors, has been shown in trials to enable early diagnosis of those bowel-cancer patients not responding to the standard cancer therapy better than other available tumor markers. Furthermore, the TexRAD markers showed the ability to assess at an early stage the likelihood of survival, distinguishing patients who will have a good prognosis from those having poor prognosis. Dr Balaji Ganeshan, one of the Sussex academics whose research led to the development of the technology, said: “By using TexRAD to scan for subtle anomalies in a tumor’s texture, researchers have been able to spot more quickly when treatments are — or are not — working and adjust treatment accordingly. “And because TexRAD simply provides an additional layer of software analysis of the MRI and CT scans that already exist as part of routine clinical practice, it is non-invasive from the patient’s point of view and potentially cost-effective to the healthcare provider.” The technology is being evaluated in a number of research institutions and university hospitals around the world. …
Several clinical trials – where women with breast cancer were given these drugs (bisphosphonates) alongside normal treatment for early-stage disease – showed that they can confer a ‘survival advantage’ and inhibit cancer spread in some women, although until now no-one has understood why. A new study by Professor Mike Rogers, Dr Tri Phan and Dr Simon Junankar from Sydney’s Garvan Institute of Medical Research has used sophisticated imaging technologies to reveal that bisphosphonates attach to tiny calcifications in tumours in mice. These calcium-drug complexes are then devoured by ‘macrophages’, immune cells that the cancer hijacks early in its development to conceal its existence. The study, which includes remarkable movies of the entire process described above, is published in the journal Cancer Discovery, now online…
Several clinical trials – where women with breast cancer were given these drugs (bisphosphonates) alongside normal treatment for early-stage disease – showed that they can confer a ‘survival advantage’ and inhibit cancer spread in some women, although until now no-one has understood why. …
Lung cancer treatment and prognosis is critically dependent on accurate staging that takes into account the extent to which cancer has spread from the primary lung tumor to other locations. Examination of lymph nodes containing lung cancer cells that have spread can be done by surgical removal, historically the standard practice, or by using a less invasive more cost effective technique called endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). …
Around 5,000 cases of DCIS, a condition where cancerous cells are contained within the milk ducts of the breast, are diagnosed each year in the UK, with two thirds diagnosed through breast screening. If left untreated, up to half of DCIS cases could progress into invasive breast cancer, but it is not possible to say which ones, so all women are offered treatment. …
The study, carried out by researchers from the London Cancer Alliance (LCA) and King’s College London investigated around 130 patients who were diagnosed with lung cancer after attending as an emergency at one of seven hospitals in south and west London. Overall, nearly half of the patients reported that something had put them off going to the doctor, including difficulty making an appointment, not being able to see their usual doctor, not having confidence in the GP, and fear of what the doctor might find. About a fifth of all patients (18 per cent) said they had not realised that their symptoms were serious.A fifth of all patients — who tended to be older, poorer and more fearful of what the doctor might find — delayed going to their doctor with their symptoms for more than 12 weeks. Three-quarters of the patients had consulted their GP about their symptoms, and one fifth had seen a GP at least three times. …